Comparison
17 20 Lyase Deficiency Isolated Included CN372394 vs 14q12 Microdeletion Syndrome C4305240
Clinical comparison between 17 20 Lyase Deficiency Isolated Included CN372394 and 14q12 Microdeletion Syndrome for differential diagnosis and treatment planning.
6 comparison axes
Onset
17 20 Lyase Deficiency Isolated Included CN372394
0-16
14q12 Microdeletion Syndrome C4305240
0-1
Onset patterns differ
Severity
17 20 Lyase Deficiency Isolated Included CN372394
severe
14q12 Microdeletion Syndrome C4305240
moderate
Different severity levels
Chronic
17 20 Lyase Deficiency Isolated Included CN372394
Chronic
14q12 Microdeletion Syndrome C4305240
Chronic
Differing course
Communicable
17 20 Lyase Deficiency Isolated Included CN372394
No
14q12 Microdeletion Syndrome C4305240
No
Different transmission
Body System
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
14q12 Microdeletion Syndrome C4305240
congenital
Same/different system
Category
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
14q12 Microdeletion Syndrome C4305240
genetic
Different category
Bottom line
17-20-lyase-deficiency-isolated-included-CN372394 and 14q12-microdeletion-syndrome-C4305240 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 20 Lyase Deficiency Isolated Included CN372394 | 14q12 Microdeletion Syndrome C4305240 | Discriminating power |
|---|---|---|---|
| Primary clinical domain | Sex-steroid deficiency may present from infancy through adolescence. | Developmental delay is the described core concern, often beginning in infancy. | High |
| Developmental pattern | Genital or pubertal development may be atypical and can vary by karyotype. | Source data support developmental delay, not a defined endocrine phenotype. | Moderate |
| Supplied severity pattern | Listed as severe, although individual impact is not established here. | Listed as moderate, but function can vary between individuals. | Low |
When to favor each condition
Choose 17 20 Lyase Deficiency Isolated Included CN372394 when
Atypical genital development or absent puberty is being evaluated
The endocrine category and onset from infancy to adolescence support steroid-synthesis assessment.
Moderate
Sex-steroid production appears impaired while cortisol status is uncertain
Isolated lyase deficiency must be separated from broader adrenal enzyme defects by specialists.
Moderate
Targeted endocrine genetic testing is more relevant than microarray
The supplied category is endocrine rather than a chromosomal microdeletion syndrome.
High
Choose 14q12 Microdeletion Syndrome C4305240 when
An infant has developmental delay and a chromosomal disorder is suspected
Infancy onset and congenital genetic classification match the supplied profile.
Moderate
Copy-number testing is the appropriate diagnostic pathway
The condition concerns a missing chromosome 14 segment, not a steroid result alone.
High
Supportive developmental care is the principal management frame
The source describes individualized supportive treatment without a specific endocrine therapy.
Moderate
How key tests differ
| Test | 17 20 Lyase Deficiency Isolated Included CN372394 | 14q12 Microdeletion Syndrome C4305240 | Interpretation |
|---|---|---|---|
| Steroid or endocrine profile | May suggest impaired sex-steroid production; no cutoff is established here. | No specific steroid abnormality is established by the source. | An abnormal laboratory result is not itself a diagnosis. |
| Genetic or chromosomal testing | Targeted endocrine gene testing may be considered; confirmation is not guaranteed. | Chromosomal microarray may identify a 14q12 deletion. | Test selection requires endocrinology or clinical genetics judgment. |
| Developmental assessment | Neurodevelopment is not defined by the supplied source. | Assessment can document delay but cannot prove the deletion. | Clinical findings need confirmatory testing and clinician review. |
Prognosis comparison
17 20 Lyase Deficiency Isolated Included CN372394
- Outcome
- Lifelong outcome is not established; the supplied course is chronic and severity severe.
- Factors
- Hormone findings, genetic confirmation, and timing of specialist care.
14q12 Microdeletion Syndrome C4305240
- Outcome
- Chronic congenital condition with variable developmental impact; supplied severity is moderate.
- Factors
- Deletion findings, associated health concerns, and available supportive services.
Time frame: Lifelong follow-up may be needed, but exact milestones are not established.
Diagnostic confirmation, associated anomalies, and coordinated care influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Sexual development | Delayed or atypical sexual development may occur; fertility impact is not quantified. A specific reproductive complication is not established. Do not assume a shared reproductive outcome. |
| Cortisol reserve | It is discussed separately from cortisol deficiency, but reserve must be confirmed. Adrenal failure is not described in the source. Do not infer adrenal-crisis risk without clinical testing. |
| Neurodevelopment | A specific developmental syndrome is not established. Developmental delay and other health concerns may affect learning and care. Severity labels do not predict individual function. |
Patient education highlights
- HighDifferent causes
One affects hormone synthesis and the other is a chromosomal deletion. Neither condition is contagious.
- HighConfirmatory testing
Abnormal blood or genetic findings need specialist interpretation and do not alone establish the diagnosis.
- MediumIndividualized care
Management is supportive and individualized. Prevalence, doses, and exact outcomes are not established here.